ethyl (3S)-3-amino-3-(4-chlorophenyl)propanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl (3S)-3-amino-3-(4-chlorophenyl)propanoate
• 化学式: C₁₁H₁₄ClNO₂
• mdl: MFCD00448267
• 分子量: 227.69
• InChiKey: SAXNGCIJNXBVHG-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] SUBSTITUTED ß-AMINO ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'ACIDES AMINÉS SS SUBSTITUÉS COMME ANTAGONISTES DU RÉCEPTEUR CXCR3
  申请人：SANOFI SA

  公开号：WO2013174485A1

  公开（公告）日：2013-11-28

  The present invention relates to compounds of formula 1 that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to the novel intermediates used in the preparation of said compounds.

  本发明涉及公式1的化合物，该化合物作为药物活性成分用于预防性和/或治疗由CXCR3趋化因子异常激活引起的疾病。此外，发明还涉及制备所述化合物的方法、包含所述化合物的药物组合物以及用于制备所述化合物的新中间体。
• Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity
  申请人：ASTEX THERAPEUTICS LIMITED

  公开号：US10544132B2

  公开（公告）日：2020-01-28

  The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.

  本发明提供了一种式 (I) 的化合物： 或同系物或其溶液或药学上可接受的盐，其中各种取代基如权利要求中定义。 此外，还提供了含有式（I）化合物的药物组合物、化合物的制造工艺和化合物的医疗用途。
• SUBSTITUTED ß-AMINO ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS
  申请人：SANOFI

  公开号：EP2852578A1

  公开（公告）日：2015-04-01
• ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY
  申请人：ASTEX THERAPEUTICS LIMITED

  公开号：US20190016708A1

  公开（公告）日：2019-01-17

  The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.